Cargando…

BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5–11 Years of Age: A Test Negative Design

In a 1:1 matched test-negative design among 5- to 11-year-olds in the Kaiser Permanente Southern California health system (n = 3984), BNT162b2 effectiveness against the omicron-related emergency department or urgent care encounters was 60% [95%CI: 47−69] <3 months post-dose-two and 28% [8−43] aft...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tartof, Sara Y, Frankland, Timothy B, Puzniak, Laura, Slezak, Jeff M, Hong, Vennis, Takhar, Harpreet, Ogun, Oluwaseye A, Simmons, Sarah, Xie, Fagen, Zamparo, Joann, Ackerson, Bradley K, Jodar, Luis, McLaughlin, John M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112675/ https://www.ncbi.nlm.nih.gov/pubmed/36715070 http://dx.doi.org/10.1093/jpids/piad005

Ejemplares similares

BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
por: Tartof, Sara Y, et al.
Publicado: (2022)

Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study
por: Tartof, Sara Y., et al.
Publicado: (2022)

Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System
por: Tartof, Sara Y., et al.
Publicado: (2023)

Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years
por: Tartof, Sara Y., et al.
Publicado: (2022)

Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants
por: Tartof, Sara Y, et al.
Publicado: (2022)

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
por: Tartof, Sara Y, et al.
Publicado: (2021)

Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study
por: Tartof, Sara Y, et al.
Publicado: (2023)

Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
por: Tartof, Sara Y, et al.
Publicado: (2022)

Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
por: Lewnard, Joseph A, et al.
Publicado: (2023)

Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age
por: Khan, Farid L., et al.
Publicado: (2022)

Impact of COVID-19 and effects of BNT162b2 on patient-reported outcomes: quality of life, symptoms, and work productivity among US adult outpatients
por: Di Fusco, Manuela, et al.
Publicado: (2022)

Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron
por: Di Fusco, Manuela, et al.
Publicado: (2023)

Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System — California, March–July 2021
por: Malden, Deborah E., et al.
Publicado: (2021)

Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome
por: Lewnard, Joseph A., et al.
Publicado: (2023)

Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine
por: McGrath, Leah J., et al.
Publicado: (2023)

Increased vaccine sensitivity of an emerging SARS-CoV-2 variant
por: Lewnard, Joseph A., et al.
Publicado: (2023)

Natural Language Processing for Improved Characterization of COVID-19 Symptoms: Observational Study of 350,000 Patients in a Large Integrated Health Care System
por: Malden, Deborah E, et al.
Publicado: (2022)

Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients
por: Slezak, Jeff, et al.
Publicado: (2021)

Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system
por: Malden, Deborah E., et al.
Publicado: (2023)

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
por: Di Noia, Vincenzo, et al.
Publicado: (2022)

Side Effects Related to BNT162b2 and CoronaVac Vaccine Requiring Emergency Department Visit
por: Yavuz, Erdal, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

The Clinical Differences between Urgent Visits and Non-Urgent Visits in Emergency Department During the Neonatal Period
por: Yang, Hyung Jun, et al.
Publicado: (2017)

Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study
por: Haas, Eric J, et al.
Publicado: (2022)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Prevention of Coronavirus Disease 2019 Among Older Adults Receiving Pneumococcal Conjugate Vaccine Suggests Interactions Between Streptococcus pneumoniae and Severe Acute Respiratory Syndrome Coronavirus 2 in the Respiratory Tract
por: Lewnard, Joseph A, et al.
Publicado: (2021)

Effectiveness of Pneumococcal Conjugate Vaccination Against Virus-Associated Lower Respiratory Tract Infection Among Adults: A Case-Control Study
por: Lewnard, Joseph A, et al.
Publicado: (2022)

BNT-162b1: Stevens-Johnson syndrome: case report
Publicado: (2021)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pf4tfi6s7gkork1t4rdbfpejse